Why did a promising heart drug fail? Doomed drug highlights complications of meddling with cholesterol. 1. The failure of a high-profile cholesterol drug has thrown a spotlight on the complicated machinery that regulates cholesterol levels. But many researchers remain confident that drugs to boost levels of good cholesterol are still one of the most promising means to combat spiralling heart disease. 2. Drug company Pfizer announced on 2 December that it was cancelling all clinical trials of torcetrapib, a drug designed to raise heart-protective high-density lipoproteins (HDLs). In a trial of 15000 patients, a safety board found that more people died or suffered cardiovascular problems after taking the drug plus a cholesterol-lowering statin than those in a control group who took the statin alone. 3. The news came as a kick in the teeth to many cardiologists because earlier tests in animals and people suggested it would lower rates of cardiovascular disease. There have been no red flags to my knowledge, says John Chapman, a specialist in lipoproteins and atherosclerosis at the National Institute for Health and Medical Research (INSERM) in Paris who has also studied torcetrapib. This cancellation came as a complete shock. 4. Torcetrapib is one of the most advanced of a new breed of drugs designed to raise levels of HDLs, which ferry cholesterol out of artery-clogging plaques to the liver for removal from the body. Specifically, torcetrapib blocks a protein called cholesterol ester transfer protein (CETP), which normally transfers the cholesterol from high-density lipoproteins to low density, plaque-promoting ones. Statins, in contrast, mainly work by lowering the bad low-density lipoproteins. Under pressure 5. Researchers are now trying to work out why and how the drug backfired, something that will not become clear until the clinical details are released by Pfizer. One hint lies in evidence from earlier trials that it slightly raises blood pressure in some patients. It was thought that this mild problem would be offset by the heart benefits of the drug. But it is possible that it actually proved fatal in some patients who already suffered high blood pressure. If blood pressure is the explanation, it would actually be good news for drug developers because it suggests that the problems are specific to this compound. Other prototype drugs that are being developed to block CETP work in a slightly different way and might not suffer the same downfall. 6. But it is also possible that the whole idea of blocking CETP is flawed, says Moti Kashyap, who directs atherosclerosis research at the VA Medical Center in Long Beach, California. When HDLs excrete cholesterol in the liver, they actually rely on LDLs for part of this process. So inhibiting CETP, which prevents the transfer of cholesterol from HDL to LDL, might actually cause an abnormal and irreversible accumulation of cholesterol in the body. Youre blocking a physiologic mechanism to eliminate cholesterol and effectively constipating the pathway, says Kashyap. Going up
雅思口语备考的一些建议
雅思口语:语音词汇和语法的三个问题
考官谈是雅思口语测评标准
雅思考试的应试小技巧
世辩赛学雅思口语-A food:Bolt
如何准备繁多的雅思口语卡片?
雅思口语中表达的礼貌技巧
雅思口语备考的三个阶段
雅思口语素材:书籍相关的实用词汇和句型
看美剧学雅思:《gossip girl》中的经典口语句型(3)
雅思口语考试常见问题169个(1-20)
雅思口语常考话题卡片分类整理(1)
看美剧学雅思:《gossip girl》中的经典口语句型(2)
雅思口语常考话题卡片分类整理(3)
雅思口语考试第一部分闯关诀窍
雅思口语part 2经典话题
雅思口语考试常见问题169个(161-169)
实例解析雅思口语备考要点
雅思口语常考话题卡片分类整理(4)
雅思口语常考话题卡片分类整理(2)
雅思口语part 3经典话题
世辩赛学雅思口语:A restaurant
雅思口语8分感想:过程与经验(上)
雅思口语迅速突破的三大方法
雅思口语第一部分常考问题(Holidays)
雅思口语常用谚语20句
雅思口语Part 1常见话题解析:年龄
雅思口语第一部分常考问题(Friends)
雅思口语常用谚语20条
备考指导:雅思口试的通关之道
不限 |
英语教案 |
英语课件 |
英语试题 |
不限 |
不限 |
上册 |
下册 |
不限 |